Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab vs Investigator's Choice in Previously Treated HNSCC
NCT06496178Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Jun 2024
- Primary completion
- Feb 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of petosemtamab in head and neck squamous cell carcinoma (HNSCC), sponsored by Genmab. Started Jun 2024; status: active, not recruiting.
02
Drugs
petosemtamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06496178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496178.